AU2012271781C1 - Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion - Google Patents

Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion Download PDF

Info

Publication number
AU2012271781C1
AU2012271781C1 AU2012271781A AU2012271781A AU2012271781C1 AU 2012271781 C1 AU2012271781 C1 AU 2012271781C1 AU 2012271781 A AU2012271781 A AU 2012271781A AU 2012271781 A AU2012271781 A AU 2012271781A AU 2012271781 C1 AU2012271781 C1 AU 2012271781C1
Authority
AU
Australia
Prior art keywords
peptide
ip3r3
angioedema
treating
induced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012271781A
Other languages
English (en)
Other versions
AU2012271781B2 (en
AU2012271781A1 (en
Inventor
Yulia A. Komarova
Asrar B. Malik
Uzma SAQIB
Stephen M. Vogel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois System
Original Assignee
University of Illinois at Urbana Champaign
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Illinois at Urbana Champaign, University of Illinois System filed Critical University of Illinois at Urbana Champaign
Publication of AU2012271781A1 publication Critical patent/AU2012271781A1/en
Publication of AU2012271781B2 publication Critical patent/AU2012271781B2/en
Application granted granted Critical
Publication of AU2012271781C1 publication Critical patent/AU2012271781C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2012271781A 2011-06-13 2012-06-13 Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion Active AU2012271781C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161496409P 2011-06-13 2011-06-13
US61/496,409 2011-06-13
PCT/US2012/042118 WO2012174028A2 (en) 2011-06-13 2012-06-13 Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion

Publications (3)

Publication Number Publication Date
AU2012271781A1 AU2012271781A1 (en) 2014-01-09
AU2012271781B2 AU2012271781B2 (en) 2017-02-16
AU2012271781C1 true AU2012271781C1 (en) 2017-09-21

Family

ID=47357694

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012271781A Active AU2012271781C1 (en) 2011-06-13 2012-06-13 Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion

Country Status (15)

Country Link
US (2) US9248198B2 (https=)
EP (1) EP2717897B1 (https=)
JP (1) JP6042425B2 (https=)
KR (1) KR102042015B1 (https=)
CN (2) CN106188232B (https=)
AU (1) AU2012271781C1 (https=)
BR (1) BR112013032108B1 (https=)
CA (1) CA2838662C (https=)
DK (1) DK2717897T3 (https=)
ES (1) ES2633343T3 (https=)
IL (1) IL229771B (https=)
MX (1) MX349146B (https=)
PL (1) PL2717897T3 (https=)
WO (1) WO2012174028A2 (https=)
ZA (1) ZA201309161B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2633343T3 (es) * 2011-06-13 2017-09-20 The Board Of Trustees Of The University Of Illionis Composiciones de péptidos y métodos para tratar lesión pulmonar, asma, anafilaxis, angioedema, síndromes de permeabilidad vascular sistémica y congestión nasal
BR112017018665A2 (pt) * 2015-03-02 2018-04-24 The Board Of Trustees Of The University Of Illinois peptídeos para inibição de angiogênese
CN110128506B (zh) * 2019-05-22 2021-03-30 中国药科大学 一种寡肽及其应用
CN110664990B (zh) * 2019-11-07 2021-03-16 江南大学 一种trpc1肽类分子在制备治疗病毒感染引起的炎症的药物中的应用
TW202204375A (zh) * 2020-04-15 2022-02-01 美商寇峇有限公司 治療冠狀病毒感染之方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US6093740A (en) * 1997-04-30 2000-07-25 Eli Lilly And Company Therapeutic treatment for skin disorders
GB9718609D0 (en) 1997-09-02 1997-11-05 Imp College Innovations Ltd Fusion protein
EP1689355A4 (en) 2003-11-06 2008-10-01 Res Dev Foundation SELECTIVE INHIBITORS OF NUCLEAR FACTOR KB ACTIVATION AND ITS USES
CA2545422C (en) * 2003-12-03 2015-06-02 Cytopia Research Pty Ltd Tubulin inhibitors
WO2007035843A2 (en) * 2005-09-21 2007-03-29 Dask Technologies, Llc Methods and compositions for organ and tissue functionality
US8304382B2 (en) * 2006-07-21 2012-11-06 Cristalia Productos Quimicos Farmaceuticos Ltda. Anti-inflammatory and anti-allergic cyclic peptides
WO2008011621A2 (en) * 2006-07-21 2008-01-24 The Penn State Research Foundation Protein kinase c zeta inhibition to treat vascular permeability
WO2009094172A2 (en) * 2008-01-22 2009-07-30 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
FR2940032B1 (fr) 2008-12-23 2013-08-09 Seb Sa Panier de cuisson d'aliments et systeme de cuisson correspondant
IT1392567B1 (it) * 2008-12-24 2012-03-09 Bioindustry Park Del Canavese S P A Uso di un peptide derivato da er-alfa per il ripristino della sensibilita' a composti antiestrogenici in cellule di tumore mammario
US20100190691A1 (en) * 2009-01-27 2010-07-29 Trojan Technologies, Ltd Delivery of nucleic acids using cell-penetrating peptides
ES2633343T3 (es) * 2011-06-13 2017-09-20 The Board Of Trustees Of The University Of Illionis Composiciones de péptidos y métodos para tratar lesión pulmonar, asma, anafilaxis, angioedema, síndromes de permeabilidad vascular sistémica y congestión nasal

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
UniProt Accession No. F2AQ33, 31 May 2011 *

Also Published As

Publication number Publication date
US9248198B2 (en) 2016-02-02
KR20140056185A (ko) 2014-05-09
CN106188232A (zh) 2016-12-07
AU2012271781B2 (en) 2017-02-16
CN103608026A (zh) 2014-02-26
CN106188232B (zh) 2020-01-07
US20140213505A1 (en) 2014-07-31
EP2717897A2 (en) 2014-04-16
CA2838662A1 (en) 2012-12-20
MX349146B (es) 2017-07-14
ZA201309161B (en) 2015-03-25
US20140155314A1 (en) 2014-06-05
WO2012174028A3 (en) 2013-02-21
PL2717897T3 (pl) 2017-09-29
WO2012174028A2 (en) 2012-12-20
ES2633343T3 (es) 2017-09-20
JP2014518211A (ja) 2014-07-28
DK2717897T3 (en) 2017-07-17
EP2717897B1 (en) 2017-04-19
AU2012271781A1 (en) 2014-01-09
US8912139B2 (en) 2014-12-16
KR102042015B1 (ko) 2019-11-07
BR112013032108A2 (pt) 2016-11-22
CA2838662C (en) 2018-07-24
CN103608026B (zh) 2016-08-24
MX2013014650A (es) 2014-01-24
BR112013032108B1 (pt) 2021-10-26
JP6042425B2 (ja) 2016-12-14
EP2717897A4 (en) 2015-01-07
IL229771B (en) 2019-07-31

Similar Documents

Publication Publication Date Title
US8912139B2 (en) Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion
KR102268883B1 (ko) 누트린-3a 및 펩티드에 의한 폐 섬유증의 저해
Xie et al. Intranasal administration of recombinant Netrin-1 attenuates neuronal apoptosis by activating DCC/APPL-1/AKT signaling pathway after subarachnoid hemorrhage in rats
Zhang et al. C5aR-mediated myocardial ischemia/reperfusion injury
CN111712252A (zh) 用于治疗疼痛和提高疼痛敏感性的肽和其它药剂
Zhou et al. Mitophagy deficiency activates stimulator of interferon genes activation and aggravates pathogenetic cardiac remodeling
CN107427549A (zh) 用于抑制血管生成的肽
Zhang et al. Intracerebroventricular administration of morphine confers remote cardioprotection—Role of opioid receptors and calmodulin
Lv et al. Cytoglobin: a novel potential gene medicine for fibrosis and cancer therapy
Li et al. Acid-sensing ion channel 3 overexpression in incisions regulated by nerve growth factor participates in postoperative nociception in rats
US20130345143A1 (en) MODULATION OF p62 FUNCTION THROUGH THE PB1 DOMAIN
Bell et al. Inhaled FMLP increases microvascular permeability in the rabbit trachea
Putney Downregulation of Protein Kinase C Inhibits Perivascular Sensory Nerve Ca2+-Sensing Receptor Signaling: P211
Ichiki Downregulation of Angiotensin II Type 1 Receptor by Liver X Receptor in Vascular Smooth Muscle Cells: P210
Gallagher ACE2 Inhibition in the Nucleus of the Solitary Tract Reduces Baroreceptor Reflex Sensitivity: P220
Raizada Overexpression of ACE 2 in the Rostral Ventrolateral Medulla Causes a Long-Term Decrease in Blood Pressure in the SHR: P215
Supowit Calcitonin Gene-Related Peptide Inhibits High Glucose-Induced Reactive Oxygen Species Production in Vascular Smooth Muscle Cells: P206
Mifflin Chronic Hypertension Enhances the Post-Synaptic Effect of Baclofen in the NTS: P214
Douglas The Novel Cannabinoid Receptor GPR55 Binds Atypical Cannabinoids but Does not Mediate Their Vasodilatory Effects: P213
Collister Role of the Median Preoptic Nucleus in Chronic AngII Induced Hypertension: P219
Douglas Dendroaspis Natriuretic Peptide Binds to the Natriuretic Peptide Clearance Receptor: Pharmacological Characterization and Therapeutic Implications: P205
Eguchi Novel Reciprocal eNOS Regulation by Protease-Activated Receptors Involving Gq, G12/13 and Rho/Rho Kinase: P204
Diz Intracisternal Injection of Angiotensin-(1–7)-Producing Fusion Protein Plasmid Lowers Blood Pressure in Hypertensive (mren2) 27 Rats: P221
Dumler Mechanical Stress Modulates SOCS-1 Expression In Human Aortic Vascular Smooth Muscle Cells: P203
HK1248101B (en) Peptides for inhibiting angiogenesis

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 15 MAR 2017

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 02 JUN 2017

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 15 MAR 2017

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 02 JUN 2017

FGA Letters patent sealed or granted (standard patent)